Abstract:Abstract Background Faecal calprotectin (Fcal) could be a non-invasive alternative to endoscopy to assess therapeutic efficacy in patients with Crohn’s disease (CD). We performed a systematic review and meta-analysis of individual data to assess the performances of FCal after anti-TNF induction therapy to predict mid-term steroids-free clinical remission (CFREM) in CD. Methods We included all the studies reporting patients with CD receiving anti-TNF agents with Fcal measurement before and after induction therapy (from 8 to 14 weeks) with follow-up > 6 months, no therapeutic intervention based on FCal during the follow-up and mid-term clinical evaluation between week 32 and week 54. CFREM was defined as CDAI < 150 and continuation of the same anti-TNF agent without steroids. Results We identified five articles including 165 patients with CD (mean age = 34.5 ± 12.8 years, median CD duration 5 years [2–12], female gender = 52.7%, active smokers = 33.3%, prior bowel resection = 25.6%, CD location (L1 = 32.1%, L2 = 15.8%, L3 = 52.1%), perianal lesions = 22.4%). The patients were treated with infliximab (50.9%), adalimumab (47.3%) or certolizumab (1.8%), and received concomitant immunosuppressants in 48.5% of the patients. Mid-term CFREM was achieved in 57.3% of the patients. Fcal level after anti-TNF induction therapy was lower in patients who achieved mid-term CFREM (100 μg/g [48–267] compared with those who did not (491 μg/g [165–856]; p < 0.001). The relative decrease of Fcal between before and after induction therapy was also associated with mid-term CFREM (p = 0.022). In multivariable analysis adjusted on CDAI, CRP and disease duration, FCal level (p = 0.014) and relative decrease of anti-TNF (p = 0.025) after induction were associated with mid-term CFREM. Cut-off values between 200 and 400 μg/g showed close performances to predict mid-term CFREM. FCal <250μg/g predicted mid-term CFREM with: Se = 73.3%[63.0%-82.1%], Spe = 67.7%[54.9%-78.8%], PPV = 75.9%[65.5%-84.4%] and NPV= 64.7%[52.2%-75.9%]. A relative decrease ≥ 50% between baseline and the end of induction was the best threshold to predict mid-term CFREM (Se = 59.6%[48.6–69.8%], Spe = 78.5%[66.5–87.7%], PPV = 79.1%[67.4–88.1%] and NPV = 58.6% [47.6–69.1%]). We found a significant study effect (ICC =0.36 ± 0.18) due to the variability according to FCal assay. The likelihood of being in CFREM at mid-term (PPV) according to the combination of CDAI, CRP and Fcal was presented in Figure 1. Conclusion The improvement of Fcal after anti-TNF induction therapy is predictive of mid-term CFREM in patients with IBD. The combination of clinical remission, CRP normalisation and FCal improvement should be a therapeutic target in patients with CD. Our work highlighted the need of international standardisation of Fcal measurement.

P950 Advancing Precision Nutritional Assessment in Inflammatory Bowel Disease (IBD): Adding Fecal Calprotectin in the Malnutrition Inflammation Risk Tool (MIRT) score

Comparison of Fecal Calprotectin and Myeloperoxidase in Predicting Outcomes in Inflammatory Bowel Disease

Clinical value of fecal calprotectin

P1161 Prevalence of undernutrition in patients with inflammatory bowel disease and improvement after nutritional advice

P497 Malnutrition in inflammatory bowel disease: a correlation between clinical and nutritional parameters

P136 Faecal calprotectin as therapeutic target in patients with Crohn’s disease treated with anti-TNF: a meta-analysis of individual data

Predicting mucosal inflammation in IBD patients using patient-reported symptom scores and a faecal calprotectin home test: protocol for a multicentre prospective validation study

P282 High Correlation Between Fecal Immunochemical Test and Fecal Calprotectin for the Evaluation of Activity in Inflammatory Bowel Disease

Body impedance analysis to estimate malnutrition in inflammatory bowel disease patients - A cross-sectional study

P364 Faecal calprotectin testing in patients presenting with lower gastrointestinal symptoms; a retrospective primary care study in the United Kingdom

P138 Novel serum markers for predicting disease activity in ulcerative colitis: results from a retrospective case-control study

Clinical Significance of Faecal Calprotectin in Differentiating Inflammatory Bowel Disease from Irritable Bowel Syndrome

P1124 Nutritional assessment and validation of GLIM Criteria in Inflammatory Bowel Disease patients

P428 Nutritional, Muscular status and micronutrient deficiencies in patients with Inflammatory Bowel Disease

P332 The role of Handgrip Strength in Nutritional Status Assessment of Patients with Inflammatory Bowel Disease. A cross-sectional study

Comparison of Fecal Calprotectin with Different Endoscopic Scores in the Assessment of Ulcerative Colitis (UC) Activity and Its Utility in Differentiating IBS from IBD

Efficacy of Noninvasive Evaluations in Monitoring Inflammatory Bowel Disease Activity: A Prospective Study in China

Calprotectin: from biomarker to biological function

Combined Use of Fecal Biomarkers in Inflammatory Bowel Diseases: Oncostatin M and Calprotectin

P412 Faecal Calprotectin as a predictor of endoscopic and histologic remission in patients with Ulcerative Colitis

Intestinal ultrasonography and fecal calprotectin for monitoring inflammation of ileal Crohn’s disease: two complementary tests